Comparative Pharmacology
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus PROMETH PLAIN.
MECLIZINE HYDROCHLORIDE vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category A/B
Category C
Antihistamine
Antihistamine